Filing Flows

Filing Flows › Health Care › Beam Therapeutics (BEAM)

Beam Therapeutics (BEAM) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Beam Therapeutics (BEAM) Q3 2026 earnings results →

Q3 2026 Revenue down 97% year over year to $307K

Beam Therapeutics made $307K in Q3 2026 (-97% Y/Y). Operating margin n/m, net loss $134M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.

Revenue$307K
Year over year-97%
Operating marginn/m
Net earnings−$134M
Operating cash flow−$111M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $307K in Q3 2026, down 97% year over year and down 37% from the previous quarter.

Operating costs exceeded revenue by $141.3M, an operating margin of -46033.2%. Total costs grew 4% against a revenue fall of 97%. The fastest-growing cost line was General & admin (+18%). The quarter ended with a net loss of $134.4M, wider than the previous quarter's $122.7M loss.

Operating cash flow was −$110.7M. Non-cash charges added back $5.4M of depreciation and $18.6M of share-based compensation. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$112.0M.

Quarterly history

Beam Therapeutics revenue by quarterBeam Therapeutics revenue by quarter$7.5MQ1 2025$8.5MQ2 2025$9.7MQ3 2025$114MQ4 2025$31.7MQ1 2026$490KQ2 2026$307KQ3 2026
Beam Therapeutics net earnings by quarterBeam Therapeutics net earnings by quarter−$108MQ1 2025−$102MQ2 2025−$113MQ3 2025$243MQ4 2025−$94.3MQ1 2026−$123MQ2 2026−$134MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 3, 2026$307K-97%n/m−$134M−$111M
Q2 202610-QAug 4, 2026$490K-94%n/m−$123M−$66.1M
Q1 202610-QMay 7, 2026$31.7M+325%-337.8%−$94.3M−$129M
Q4 202510-KFeb 24, 2026$114M+280%-15.3%$243M−$83.3M
Q3 202510-QNov 4, 2025$9.7M-32%n/m−$113M−$81.5M
Q2 202510-QAug 5, 2025$8.5M-28%n/m−$102M−$76.5M
Q1 202510-QMay 6, 2025$7.5M+0.8%n/m−$108M−$104M

Charts

Beam Therapeutics: revenue growth, year over year and quarter over quarterBeam Therapeutics: revenue growth, year over year and quarter over quarterY/YQ/Q+1%Q1 2025-28%+13%Q2 2025-32%+15%Q3 2025+280%+400%Q4 2025+325%-72%Q1 2026-94%-98%Q2 2026-97%-37%Q3 2026
Latest (Q3 2026): Y/Y -97%, Q/Q -37%.
Beam Therapeutics: where the cash came from (+) and went (−), TTM to Q3 2026Beam Therapeutics: where the cash came from (+) and went (−), TTM to Q3 2026Operating cash flow−$389MOther investing$235MOther financing$96.0MCash drawn (+) / kept (−)$54.6MShares issued$12.4MCapital spending−$9.6M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Beam Therapeutics: profit against cash, quarter by quarterBeam Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$90.4M−$76.4MQ4 2024−$108M−$104MQ1 2025−$102M−$76.5MQ2 2025−$113M−$81.5MQ3 2025$243M−$83.3MQ4 2025−$94.3M−$129MQ1 2026−$123M−$66.1MQ2 2026−$134M−$111MQ3 2026
Latest (Q3 2026): Net income −$134M, Operating cash flow −$111M.
Beam Therapeutics: diluted shares by fiscal yearBeam Therapeutics: diluted shares by fiscal year47MFY202064MFY202170MFY202277MFY202382MFY202499MFY2025
+111.6% since FY2020: more shares outstanding (issuance, stock pay).
Beam Therapeutics in its industry: growth against margin (76 companies, SIC 2836)Beam Therapeutics in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVATWSTIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCSBRCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZALGSXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURPROKCRDFAIMVIVSBEAM (-97%, -100%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

In its own words, from its 8-K, filed Aug 4, 2026.

Beam Therapeutics against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -97% against the peers' median +11%.

CompanyQuarterRevenueY/YOp. margin
BEAM Beam TherapeuticsQ3 2026$307K-97%n/m
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: Beam Therapeutics 10-Q on SEC EDGAR · CIK 1745999 · Biological Products, (No Diagnostic Substances)

Guidance and outlook

Beam Therapeutics: what its forward-looking statements are about (10-Q filed 2026-11-03)Beam Therapeutics: what its forward-looking statements are about (10-Q filed 2026-11-03)Other16Costs11Legal & regulation5Demand5Products3Supply chain1Financing1
42 statements; tone +0.21 (−1 all cautious, +1 all confident); 5 hedged.
Beam Therapeutics: outlook statements against the filing beforeBeam Therapeutics: outlook statements against the filing beforeConfident10Cautious1

13F: who owns BEAM and who is buying

Largest holders of BEAM (13F)Largest holders of BEAM (13F)FMR LLC$433MARK Investment Management LLC$351MBlackRock$309MVanguard Group$255MState Street$200MVanguard Portfolio Management LLC$169MVanguard Capital Management LLC$158MArch Venture Management, LLC$156MSumitomo Mitsui Trust Group$119MNikko Asset Management Americas$119M
Funds' net buying of BEAM by quarter (13F)Funds' net buying of BEAM by quarter (13F)$13.7M2024-09−$14.6M2024-12$352M2025-03$129M2025-06−$57.6M2025-09$10.4M2025-12$52.9M2026-03$44.2M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on BEAM

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare BEAM with

中文版：Beam Therapeutics（BEAM）财报

Español · Français